

12th September, 2019

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB.: DISCLOSURE PURSUANT TO REGULATION 30 OF SEBI (LODR) REGULATIONS, 2015

Dear Sir,

With reference to the captioned subject, we are pleased to inform that Drug Controller General of India has approved MDR Tuberculosis (TB) Medicine Bedaquiline Fumarate (BULK) for Dishman for production in India.

Innovator company of this drug, M/S Janssen Pharmaceutica, Europe had applied for license for export as well as domestic (India) supply with all required data and clinical trial records required by the office of Drug Controller General of India.

We also want to assure the world that Dishman has adequate production facility to produce required quantity of this life saving medicine.

Kindly take the same on your record.

Thanking You,

Yours faithfully,
For, Dishman Carbogen Amcis Limited


Shrima Dave
Company Secretary



Dishman Carbogen Amcis Limited
(Formerly Carbogen Amcis (I) Ltd)

DISHMAN CORPORATE HOUSE
Iscon-Bopal Road, Ambli, Ahmedabad-380 058. (India)
Phone : +91 (0) 2717 420100 / 420124
E-mail : dcal@dishmangroup.com
Website : www.dishmangroup.com

Regd. Off.: Bhadra-Raj Chambers, Swastik Cross Road,
Navrangpura, Ahmedabad-380 009. (India)
Phone : +91 (0) 79 26443053 / 26445807 / 26560089
Fax : +91 (0) 79 26420198

Government Recognised Export House
CIN No. : L74900GJ2007PLC051338